SCHEMBL6989171

SCHEMBL6989171

COC(=O)c1c(Nc2cc(F)ccc2N)sc2ccc(C)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
TP53 P04637 1/20 0.42
CISD2 Q8N5K1 4/20 0.38
IKBKB O14920 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
CMA1 P23946 2/20 0.37
IDO1 P14902 2/20 0.36
CNR2 P34972 1/20 0.36
LMNA P02545 2/20 0.35
GAA P10253 2/20 0.35
HTT P42858 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
TNF P01375 1/20 0.35
HPGD P15428 1/20 0.35
NR2F2 P24468 1/20 0.35
KMT2A Q03164 1/20 0.35
MCL1 Q07820 1/20 0.35
KLF5 Q13887 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6993052 0.85 LMNA (0.41) MAPTCISD2L3MBTL1TDP1CMA1
SCHEMBL6991782 0.83 ALDH1A1 (0.41) MAPTTP53L3MBTL1TDP1CMA1
SCHEMBL6995665 0.82 MAPT (0.41) MAPTCISD2TDP1LMNAGAA
SCHEMBL6993864 0.79 SMN1; SMN2 (0.43) MAPTLMNAGAAKDM4EHPGD
SCHEMBL6997282 0.77 SMN1; SMN2 (0.51) MAPTTDP1LMNAGAAHTT
SCHEMBL7000919 0.76 PRKCZ (0.44) MAPTTP53LMNAGAAHTT
SCHEMBL6991094 0.74 CISD2 (0.51) MAPTCISD2L3MBTL1TDP1IDO1
SCHEMBL6995647 0.74 MAPT (0.40) MAPTTP53L3MBTL1GAAKDM4E
SCHEMBL6996750 0.74 SMN1; SMN2 (0.45) MAPTCISD2TDP1LMNAGAA
SCHEMBL6995638 0.73 KMT2A (0.43) MAPTTP53L3MBTL1TDP1CMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT MAPT 15/4885TP53 414/4885CISD2 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.